112 related articles for article (PubMed ID: 11942993)
1. Intrarenal bacillus Calmette-Guérin therapy for carcinoma in situ of the upper urinary tract: long-term follow-up and natural course in cases of failure.
Kawakami M
BJU Int; 2002 Apr; 89(6):640; author reply 640. PubMed ID: 11942993
[No Abstract] [Full Text] [Related]
2. Intrarenal bacillus Calmette-Guérin therapy for carcinoma in situ of the upper urinary tract: long-term follow-up and natural course in cases of failure.
Okubo K; Ichioka K; Terada N; Matsuta Y; Yoshimura K; Arai Y
BJU Int; 2001 Sep; 88(4):343-7. PubMed ID: 11564018
[TBL] [Abstract][Full Text] [Related]
3. [Treatment outcome of intrarenal Bacillus Calmette-Guerin therapy for carcinoma in situ of the upper urinary tract].
Anan G; Suyama T; Takeuchi N; Nakamura K; Sakamoto S; Nihei N; Ichikawa T
Hinyokika Kiyo; 2013 May; 59(5):261-4. PubMed ID: 23719131
[TBL] [Abstract][Full Text] [Related]
4. Impact of bacillus Calmette-Guérin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy.
Horiguchi H; Yoneyama T; Hatakeyama S; Tokui N; Sato T; Fujita N; Yamamoto H; Tobisawa Y; Yoneyama T; Hashimoto Y; Koie T; Yoshikawa K; Narita S; Kawaguchi T; Ohyama C
Med Oncol; 2018 Feb; 35(4):41. PubMed ID: 29480348
[TBL] [Abstract][Full Text] [Related]
5. Intravesical Bacillus Calmette-Guérin in immunosuppressed patients with carcinoma in situ.
Bonarriba CR; de la Cruz-Ruiz M; Gómez-Marqués G
Nefrologia; 2013; 33(3):429-31. PubMed ID: 23712234
[No Abstract] [Full Text] [Related]
6. Bacillus Calmette-Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract.
Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Nishimura K; Takaha N; Takahara S; Okuyama A
Eur Urol; 2000 Dec; 38(6):701-4;discussion 705. PubMed ID: 11111187
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract.
Hayashida Y; Nomata K; Noguchi M; Eguchi J; Koga S; Yamashita S; Hayashi M; Kanatake H
Urology; 2004 Jun; 63(6):1084-8. PubMed ID: 15183955
[TBL] [Abstract][Full Text] [Related]
8. Editorial comment to Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group.
Mostafid H
Int J Urol; 2010 Sep; 17(9):766-7. PubMed ID: 20727047
[No Abstract] [Full Text] [Related]
9. Editorial comment: Impact of smoking on outcomes after intravesical bacillus Calmette-Guérin therapy for urothelial carcinoma not invading muscle of the bladder.
Lamm D
BJU Int; 2011 Aug; 108(4):530. PubMed ID: 21794065
[No Abstract] [Full Text] [Related]
10. Percutaneous sequential bacillus Calmette-Guèrin and mitomycin C for panurothelial carcinomatosis.
Di Stasi SM; Giannantoni A; Stephen RL; Storti L; Attisani F; Sansalone S; Virgili G
Can J Urol; 2005 Dec; 12(6):2895-8. PubMed ID: 16401376
[TBL] [Abstract][Full Text] [Related]
11. Re: Willem Oosterlinck, Ziya Kirkali,Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTCGenito-urinary Group Randomized Phase 2 Trial (30993). Eur Urol 2011;59:438-46.
Ooi WL; Stockler M; Hayne D
Eur Urol; 2011 Jul; 60(1):e1; author reply e2-3. PubMed ID: 21489685
[No Abstract] [Full Text] [Related]
12. Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group.
Koga H; Ozono S; Tsushima T; Tomita K; Horiguchi Y; Usami M; Hirao Y; Akaza H; Naito S;
Int J Urol; 2010 Sep; 17(9):759-66. PubMed ID: 20604814
[TBL] [Abstract][Full Text] [Related]
13. [Intrarenal bacillus Calmette-Guerin therapy for carcinoma in situ of the upper urinary tract].
Okubo K; Ishitoya S; Maeda H; Suzuki Y; Arai Y
Nihon Hinyokika Gakkai Zasshi; 1997 Mar; 88(3):386-90. PubMed ID: 9125861
[TBL] [Abstract][Full Text] [Related]
14. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results.
Losa A; Hurle R; Lembo A
J Urol; 2000 Jan; 163(1):68-71; discussion 71-2. PubMed ID: 10604316
[TBL] [Abstract][Full Text] [Related]
15. Prostatorectal fistula following intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the urinary bladder.
Enatsu N; Ota T; Ochi A
Int J Urol; 2010 Sep; 17(9):822-3. PubMed ID: 20727055
[No Abstract] [Full Text] [Related]
16. Interstitial pneumonitis secondary to intravesical bacillus calmette-guerin for carcinoma in-situ of the bladder.
Diner EK; Verghese M
Int Braz J Urol; 2004; 30(5):400-2. PubMed ID: 15610574
[TBL] [Abstract][Full Text] [Related]
17. Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer.
Miyazaki J; Hinotsu S; Ishizuka N; Naito S; Ozono S; Akaza H; Nishiyama H
Jpn J Clin Oncol; 2013 Aug; 43(8):827-34. PubMed ID: 23858038
[TBL] [Abstract][Full Text] [Related]
18. [Intrarenal Bacillus Calmette-Guerin perfusion therapy was effective for carcinoma in situ of the upper urinary tract after ileal conduit replacement : a case report].
Hayashi T; Yamanaka Y; Kinjo T; Katayama K; Kamoto A; Mori N; Yoshioka T
Hinyokika Kiyo; 2014 Apr; 60(4):175-8. PubMed ID: 24882229
[TBL] [Abstract][Full Text] [Related]
19. Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ.
Rosevear HM; Lightfoot AJ; Birusingh KK; Maymí JL; Nepple KG; O'Donnell MA;
J Urol; 2011 Sep; 186(3):817-23. PubMed ID: 21788050
[TBL] [Abstract][Full Text] [Related]
20. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance.
Griffiths TR; Charlton M; Neal DE; Powell PH
J Urol; 2002 Jun; 167(6):2408-12. PubMed ID: 11992047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
